113 related articles for article (PubMed ID: 20597484)
1. Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors.
Zambon A; Ménard D; Suijkerbuijk BM; Niculescu-Duvaz I; Whittaker S; Niculescu-Duvaz D; Nourry A; Davies L; Manne HA; Lopes F; Preece N; Hedley D; Ogilvie LM; Kirk R; Marais R; Springer CJ
J Med Chem; 2010 Aug; 53(15):5639-55. PubMed ID: 20597484
[TBL] [Abstract][Full Text] [Related]
2. Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF).
Niculescu-Duvaz D; Gaulon C; Dijkstra HP; Niculescu-Duvaz I; Zambon A; Ménard D; Suijkerbuijk BM; Nourry A; Davies L; Manne H; Friedlos F; Ogilvie L; Hedley D; Whittaker S; Kirk R; Gill A; Taylor RD; Raynaud FI; Moreno-Farre J; Marais R; Springer CJ
J Med Chem; 2009 Apr; 52(8):2255-64. PubMed ID: 19323560
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment.
Smalley KS; Flaherty KT
Future Oncol; 2009 Aug; 5(6):775-8. PubMed ID: 19663727
[TBL] [Abstract][Full Text] [Related]
4. BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring.
Nourry A; Zambon A; Davies L; Niculescu-Duvaz I; Dijkstra HP; Ménard D; Gaulon C; Niculescu-Duvaz D; Suijkerbuijk BM; Friedlos F; Manne HA; Kirk R; Whittaker S; Marais R; Springer CJ
J Med Chem; 2010 Mar; 53(5):1964-78. PubMed ID: 20148563
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
6. Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.
Ménard D; Niculescu-Duvaz I; Dijkstra HP; Niculescu-Duvaz D; Suijkerbuijk BM; Zambon A; Nourry A; Roman E; Davies L; Manne HA; Friedlos F; Kirk R; Whittaker S; Gill A; Taylor RD; Marais R; Springer CJ
J Med Chem; 2009 Jul; 52(13):3881-91. PubMed ID: 19473026
[TBL] [Abstract][Full Text] [Related]
7. Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group.
Suijkerbuijk BM; Niculescu-Duvaz I; Gaulon C; Dijkstra HP; Niculescu-Duvaz D; Ménard D; Zambon A; Nourry A; Davies L; Manne HA; Friedlos F; Ogilvie LM; Hedley D; Lopes F; Preece NP; Moreno-Farre J; Raynaud FI; Kirk R; Whittaker S; Marais R; Springer CJ
J Med Chem; 2010 Apr; 53(7):2741-56. PubMed ID: 20199087
[TBL] [Abstract][Full Text] [Related]
8. Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure.
Kerekes AD; Esposite SJ; Doll RJ; Tagat JR; Yu T; Xiao Y; Zhang Y; Prelusky DB; Tevar S; Gray K; Terracina GA; Lee S; Jones J; Liu M; Basso AD; Smith EB
J Med Chem; 2011 Jan; 54(1):201-10. PubMed ID: 21128646
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 3H-imidazo[4,5-b]pyridines as potent c-Met kinase inhibitors: design, synthesis, and biological evaluation.
Chen D; Wang Y; Ma Y; Xiong B; Ai J; Chen Y; Geng M; Shen J
ChemMedChem; 2012 Jun; 7(6):1057-70. PubMed ID: 22581753
[TBL] [Abstract][Full Text] [Related]
10. Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.
Mathieu S; Gradl SN; Ren L; Wen Z; Aliagas I; Gunzner-Toste J; Lee W; Pulk R; Zhao G; Alicke B; Boggs JW; Buckmelter AJ; Choo EF; Dinkel V; Gloor SL; Gould SE; Hansen JD; Hastings G; Hatzivassiliou G; Laird ER; Moreno D; Ran Y; Voegtli WC; Wenglowsky S; Grina J; Rudolph J
J Med Chem; 2012 Mar; 55(6):2869-81. PubMed ID: 22335519
[TBL] [Abstract][Full Text] [Related]
11. Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold.
Niculescu-Duvaz I; Roman E; Whittaker SR; Friedlos F; Kirk R; Scanlon IJ; Davies LC; Niculescu-Duvaz D; Marais R; Springer CJ
J Med Chem; 2008 Jun; 51(11):3261-74. PubMed ID: 18473434
[TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.
Ashwell MA; Lapierre JM; Brassard C; Bresciano K; Bull C; Cornell-Kennon S; Eathiraj S; France DS; Hall T; Hill J; Kelleher E; Khanapurkar S; Kizer D; Koerner S; Link J; Liu Y; Makhija S; Moussa M; Namdev N; Nguyen K; Nicewonger R; Palma R; Szwaya J; Tandon M; Uppalapati U; Vensel D; Volak LP; Volckova E; Westlund N; Wu H; Yang RY; Chan TC
J Med Chem; 2012 Jun; 55(11):5291-310. PubMed ID: 22533986
[TBL] [Abstract][Full Text] [Related]
13. The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase.
Xie P; Streu C; Qin J; Bregman H; Pagano N; Meggers E; Marmorstein R
Biochemistry; 2009 Jun; 48(23):5187-98. PubMed ID: 19371126
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds.
Okaniwa M; Hirose M; Imada T; Ohashi T; Hayashi Y; Miyazaki T; Arita T; Yabuki M; Kakoi K; Kato J; Takagi T; Kawamoto T; Yao S; Sumita A; Tsutsumi S; Tottori T; Oki H; Sang BC; Yano J; Aertgeerts K; Yoshida S; Ishikawa T
J Med Chem; 2012 Apr; 55(7):3452-78. PubMed ID: 22376051
[TBL] [Abstract][Full Text] [Related]
15. Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.
Gould AE; Adams R; Adhikari S; Aertgeerts K; Afroze R; Blackburn C; Calderwood EF; Chau R; Chouitar J; Duffey MO; England DB; Farrer C; Forsyth N; Garcia K; Gaulin J; Greenspan PD; Guo R; Harrison SJ; Huang SC; Iartchouk N; Janowick D; Kim MS; Kulkarni B; Langston SP; Liu JX; Ma LT; Menon S; Mizutani H; Paske E; Renou CC; Rezaei M; Rowland RS; Sintchak MD; Smith MD; Stroud SG; Tregay M; Tian Y; Veiby OP; Vos TJ; Vyskocil S; Williams J; Xu T; Yang JJ; Yano J; Zeng H; Zhang DM; Zhang Q; Galvin KM
J Med Chem; 2011 Mar; 54(6):1836-46. PubMed ID: 21341678
[TBL] [Abstract][Full Text] [Related]
16. Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 1.
Kaieda A; Takahashi M; Fukuda H; Okamoto R; Morimoto S; Gotoh M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Sugimoto H; Okada K; Snell G; Bertsch R; Nguyen J; Sang BC; Miwatashi S
ChemMedChem; 2019 May; 14(10):1022-1030. PubMed ID: 30945818
[TBL] [Abstract][Full Text] [Related]
17. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells.
Garamvölgyi R; Dobos J; Sipos A; Boros S; Illyés E; Baska F; Kékesi L; Szabadkai I; Szántai-Kis C; Kéri G; Őrfi L
Eur J Med Chem; 2016 Jan; 108():623-643. PubMed ID: 26724730
[TBL] [Abstract][Full Text] [Related]
19. Diverse heterocyclic scaffolds as allosteric inhibitors of AKT.
Kettle JG; Brown S; Crafter C; Davies BR; Dudley P; Fairley G; Faulder P; Fillery S; Greenwood H; Hawkins J; James M; Johnson K; Lane CD; Pass M; Pink JH; Plant H; Cosulich SC
J Med Chem; 2012 Feb; 55(3):1261-73. PubMed ID: 22248236
[TBL] [Abstract][Full Text] [Related]
20. Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing.
Reader JC; Matthews TP; Klair S; Cheung KM; Scanlon J; Proisy N; Addison G; Ellard J; Piton N; Taylor S; Cherry M; Fisher M; Boxall K; Burns S; Walton MI; Westwood IM; Hayes A; Eve P; Valenti M; de Haven Brandon A; Box G; van Montfort RL; Williams DH; Aherne GW; Raynaud FI; Eccles SA; Garrett MD; Collins I
J Med Chem; 2011 Dec; 54(24):8328-42. PubMed ID: 22111927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
